FDA warning letters to 22 CBD E-Commerce businesses provide guidance for the industry

The United States Food and Drug Administration (FDA) has recently published 22 detailed warning letters sent late in 2019 to firms that “marketed unapproved new drugs that allegedly contained cannabidiol (CBD)”. These detailed letters contain valuable insights into the FDA’s thinking about interstate CBD sales and also guidance for hundreds of other CBD merchants on what kind of activities, including marketing copy, FDA sees as unacceptable. TLDR: don’t claim CBD cures any disease. Here’s a brief breakdown of what the FDA said.

Continue reading